Concinnity Genetics, an Edinburgh-based company, has successfully raised £3M in funding to advance their gene therapy innovations.
- Established in 2023, Concinnity Genetics specializes in developing gene therapies with innovative control mechanisms.
- The funding round was notably supported by investors like Eos Advisory and Scottish Enterprise, showcasing strong confidence in Concinnity’s potential.
- Concinnity’s technology combines synthetic biology with AI, positioning it as a game-changer in making gene therapies safer.
- The investment reinforces the strength of Edinburgh’s biotech landscape and aims to catalyze future health solutions.
Concinnity Genetics, a pioneering health tech company based in Edinburgh, has secured £3 million through an oversubscribed funding round. The company, founded in 2023, is engaging in the development of revolutionary gene therapies that incorporate control mechanisms to enhance safety. ‘Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible,’ said Jessica Birt, CEO and co-founder.
The funding round was spearheaded by Scottish investor Eos Advisory. Eos’s managing partner, Andrew McNeill, noted that Concinnity aligns perfectly with their commitment to supporting groundbreaking Scottish science and addressing critical needs in gene therapy. ‘By combining synthetic biology and AI-machine learning, the Concinnity technology has been described as the
holy grail for emerging gene therapies,
‘ he mentioned, emphasizing the dual benefits of improved effectiveness and safety.
The investment also drew significant contributions from Scottish Enterprise, Old College Capital – the University of Edinburgh’s venture investment fund, and Maven Capital Partners. Dr. Andrea Taylor of Edinburgh Innovations highlighted Edinburgh’s strength in engineering biology, which fuels advanced therapeutics and solutions that impact future health. She expressed optimism about the potential for sophisticated gene control systems to revolutionize treatment possibilities, aligning with the University of Edinburgh’s core mission areas.
Concinnity’s innovative use of synthetic biology paired with AI positions it at the forefront of the biotechnological landscape, enhancing the safety and efficacy of gene therapies. This funding not only fortifies Concinnity’s trajectory in groundbreaking research but also underscores the vibrant biotech ecosystem in Edinburgh.
Concinnity Genetics’ successful funding secures their path to innovating safer gene therapies, reinforcing Edinburgh’s leading role in health tech advancements.